Long-acting second-generation and oral antipsychotics for substance use disorders and psychotic symptoms: Prescribing attitudes among Italian psychiatrists

Mariangela Corbo, Giovanni Martinotti, Andrea Aguglia, Virginio Salvi, Andrea Amerio, Salvatore Calò, Laura Fusar-Poli, Gianluca Serafini, Maria Signorelli, Mario Amore, Claudio Mencacci, Guido Di Sciascio, Giovanni Biggio, Eugenio Aguglia, Massimo Di Giannantonio

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To explore Italian psychiatrists' attitudes toward the off-label use of second generation antipsychotics (SGAs) in patients with substance use disorder and psychotic symptoms. Design and Methods: A sample of 300 Italian psychiatrists associated with the Italian Society of Neuropsychopharmacology was randomly selected to complete a survey about the off-label prescription of SGAs. Findings: Oral aripiprazole (32.7%), olanzapine (30.2%), and quetiapine (25.2%) were considered “appropriate.” Long-acting antipsychoticss were generally considered “inappropriate.”. Practice Implications: Our findings reflect a substantial level of uncertainty and a lack of coherent clinical guidance within the realm of dual diagnosis treatment. Therefore, they emphasize the need to develop specific guidelines to improve the management of pharmacotherapy among this population.

Original languageEnglish
JournalPerspectives in Psychiatric Care
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • off-label
  • psychotic symptoms
  • second-generation antipsychotics
  • substance abuse

ASJC Scopus subject areas

  • Phychiatric Mental Health

Fingerprint Dive into the research topics of 'Long-acting second-generation and oral antipsychotics for substance use disorders and psychotic symptoms: Prescribing attitudes among Italian psychiatrists'. Together they form a unique fingerprint.

Cite this